Drug-Induced Autoimmune Hepatitis Post Acute Liver Injury From Skullcap Supplements: An Unfortunate Case of Herbal Toxicity Nimish Thakral MD, Venkata Rajesh Konjeti MD, Jens Rosenau MD University of Kentucky College of Medicine, Department of Digestive Diseases and Nutrition

BACKGROUND



The use of herbal medicinal products (HMP) has exponentially increased over the last three decades with approximately 25% Americans reporting HMP use at some point in their life.



Skullcap (Scutellaria lateriflora) is a flowering plant native to North America that has been implicated in rare cases of liver injury.




We describe a rare case of severe drug induced liver injury (DILI) and de-novo autoimmune hepatitis resulting from the use of skullcap supplements.

CASE PRESENTATION


62-year-old Caucasian woman with a h/o of Sjogren's disease presenting with new onset jaundice.



- Labs on presentation: Alkaline Phosphatase (Alk Phos) 164 IU/L, AST 1091 IU/L, ALT 980 IU/L, Total Bilirubin (T bili) 9.5, INR 2.4. (Normal 4 months prior to presentation)
- **MRI/MRCP:** Unremarkable
- Patient denied any history of liver disease but admitted to using Skullcap supplements over the last month for insomnia
- Workup for chronic liver disease negative. ANA was chronically positive - 1:1280. **IgG elevated at 2573 mg/dl. Initial Liver biopsy:** Resolving centrilobular necrosis with predominant eosinophilic inflammation.
- LFT's downtrended over the next 72 hours. Patient was discharged with outpatient follow up. Re-admitted 1 month later due to worsening jaundice and acute kidney injury
- Labs on readmission: Alk Phos 619 IU/L, AST 1222 IU/L, ALT 540 IU/L, T bili 6.6 mg/dl. ANA 1:160, IgG 2023 **Repeat liver biopsy:** Extensive plasma cells consistent with drug induced autoimmune hepatitis
- liver-kidney Outcome: Listed for simultaneous transplantation but patient recovered without requiring a transplant.







Histology: **Top**: Initial biopsy showing confluent centrilobular necrosis with interspersed eosinophils (White arrow). Middle: Resolving centrilobular necrosis with plasma cells (Black arrow).

Bottom: Immunohistochemical staining of plasma cells with CD 138 (Green arrow).

CONCLUSION



HMP'S continue to be a major contributor to the annual incidence of DILI.



Given the lack of FDA regulation on dietary supplements and HMP's the incidence continues to rise.



Implementation of a centralized resource for documentation and reporting can help in reducing under-reporting of DILI.

REFERENCES

- Björnsson, E., Talwalkar, J., Treeprasertsuk, S., Kamath, P.S., Takahashi, N., Sanderson, S., Neuhauser, M. and Lindor, K. (2010), Drug-induced autoimmune hepatitis: Clinical characteristics and prognosis. Hepatology, 51: 2040-2048. https://doi.org/10.1002/hep.23588
- Yang L, Aronsohn A, Hart J, Jensen D. Herbal hepatoxicity from Chinese skullcap: A case report. World J Hepatol. 2012 Jul 27;4(7):231-3. doi: 10.4254/wjh.v4.i7.231. PMID: 22855699; PMCID: PMC3409358. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012-. Skullcap. [Updated 2020 Mar 28]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK548757/